N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=115 ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
N/A N=102 Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=44 S0916, MLN1202 in Treating Patients With Bone Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: uNTX Response Rate at 43 Days — 14 percentage of participants
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Phase 3 N=261 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Breast Cancer · Lung Cancer · Metastatic Cancer
Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844
Phase 2 N=12 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Phase 2 N=45 Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
N/A N=15 Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
Prostate Adenocarcinoma
Primary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants
Phase 3 N=437 A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Phase 2 N=114 Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Cancer
Primary: Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy — 10; 0; 0 Participants
N/A N=850 Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
Metastatic Cancer · Pain
Primary: Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment — 28.0; 32.0 percentage of participants — p=0.03
Phase 3 N=1,822 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Breast Adenocarcinoma · DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma
Primary: Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization — 67.6; 67.9 percentage of participants — p=<=.05
Phase 2 N=78 Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Maximum Pain Level Decreased by ≥ 2 Points at 2 Months After Radiofrequency Ablation (RFA) — 83.6 percentage of participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
N/A N=73 Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases
Pain · Neoplasm Metastasis · Bone Metastasis of Diverse Origins
Primary: Change From Baseline in Worst Pain Scores as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) at Week 8 — 7.26; -2.61 score on a scale — p=0.0746
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=43 A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Breast Cancer · Metastatic Bone Disease
Primary: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 — -73; -77 Percentage change
N/A N=11 PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Prostate Cancer
Primary: PET Response Rate in Metastatic Prostate Cancer Patients Treated With Zoledronate Therapy. — .091 Proportion of participants with response
Phase 2 N=20 Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
Prostate Cancer Metastatic to Bone
Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants
Phase 3 N=1,776 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Bone Metastases
Primary: Time to the First On-Study Skeletal-Related Event (Non-Inferiority) — 496.0; 625.0 Days — p=0.0007
Phase 2 N=36 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
Phase 2 N=60 To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370
Phase 3 N=48 Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
Bone Marrow Edema
Primary: Reduction of the Edema Area — 64.53; 23.97 percentage of edema volume — p==0.006
Phase 3 N=485 A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
Fractures, Bone
Primary: Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)…
Phase 3 N=1,901 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Bone Metastases
Primary: Time to the First On-Study SRE (Non-inferiority) — 521.0; 629.0 Days — p=0.0002
Phase 4 N=44 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
First or Second Line HER2-negative Breast Cancer · Metastatic Disease Without Bone Metastasis
Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants
Phase 3 N=425 Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Breast Cancer With Bone Metastasis
Primary: Annual Overall Skeletal Morbidity Rate (SMR) — 0.26; 0.22 Number of Skeletal Events per Year
Phase 1 N=23 Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Solid Tumor · Osteosarcoma
Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs